4.7 Review

Tanshinone IIA: a Chinese herbal ingredient for the treatment of atherosclerosis

Journal

FRONTIERS IN PHARMACOLOGY
Volume 14, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2023.1321880

Keywords

tanshinone IIA; vascular endothelial cells; vascular smooth muscle cells; atherosclerosis; plaques; adverse drug reactions; adhesion

Ask authors/readers for more resources

Tanshinone IIA (Tan IIA), a fat-soluble compound extracted from Salvia miltiorrhiza, has a protective effect against atherosclerosis (AS). It improves AS through multiple pathways, including inhibiting oxidative stress and inflammatory damage, improving endothelial cell function, reducing vascular smooth muscle cell proliferation and migration, stabilizing fibrous cap of atherosclerotic plaque, and inhibiting inflammation and foam cell formation. However, there is a lack of high-quality evidence-based medical data on the efficacy of Tan IIA in AS treatment, and a randomized controlled clinical trial is recommended to evaluate its exact efficacy.
Tanshinone IIA (Tan IIA) is a fat-soluble compound extracted from Salvia miltiorrhiza, which has a protective effect against atherosclerosis (AS). Tan IIA can inhibit oxidative stress and inflammatory damage of vascular endothelial cells (VECs) and improve endothelial cell dysfunction. Tan IIA also has a good protective effect on vascular smooth muscle cells (VSMCs). It can reduce vascular stenosis by inhibiting the proliferation and migration of vascular smooth muscle cells (VSMCs), and improve the stability of the fibrous cap of atherosclerotic plaque by inhibiting apoptosis and inflammation of VSMCs. In addition, Tan IIA inhibits the inflammatory response of macrophages and the formation of foam cells in atherosclerotic plaques. In summary, Tan IIA improves AS through a complex pathway. We propose to further study the specific molecular targets of Tan IIA using systems biology methods, so as to fundamentally elucidate the mechanism of Tan IIA. It is worth mentioning that there is a lack of high-quality evidence-based medical data on Tan IIA treatment of AS. We recommend that a randomized controlled clinical trial be conducted to evaluate the exact efficacy of Tan IIA in improving AS. Finally, sodium tanshinone IIA sulfonate (STS) can cause adverse drug reactions in some patients, which needs our attention.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available